Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423691 · ClinicalTrials.gov registry record · Phase 1
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
A Phase 1 study of Myelofibrosis, sponsored by Cellenkos.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 4
- Study locations
NCT05423691 is a Phase 1 study of Myelofibrosis that is actively recruiting participants, run by Cellenkos. The registered enrollment target is 24 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05423691, a Phase 1 study of Myelofibrosis, is actively recruiting participants, sponsored by Cellenkos.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 4
- Study locations
Study Summary
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
Conditions Studied
Interventions
- DRUG CK0804
Study Locations (4)
New York
- Columbia University - New York
- Montefiore Einstein Cancer Center - The Bronx
California
- UC Davis Health - Sacramento
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-12-27 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05423691
The ClinicalTrials.gov registry entry for NCT05423691 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (88% lower). The listed sponsor is Cellenkos, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which CK0804 is the first listed.
NCT05423691 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, California, Texas.
Frequently Asked Questions
What is clinical trial NCT05423691 about?
NCT05423691 is a clinical study titled "Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs". To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
What is the current status of trial NCT05423691?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-12-27. Estimated completion is 2026-12-30.
What conditions does trial NCT05423691 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT05423691?
The interventions under investigation include: CK0804 (DRUG).
Who is sponsoring clinical trial NCT05423691?
This trial is sponsored by Cellenkos, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05423691 being conducted?
This trial has 4 study locations across California, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.